AI could spot Alzheimer's years before symptoms worsen
NCT ID NCT07652931
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
The AHEAD study is testing whether artificial intelligence can help detect early signs of Alzheimer's disease in people who feel their memory is slipping but still test normal. Researchers will use brain scans, eye tests, and blood markers to identify those at highest risk. High-risk participants will receive a 6-month program including brain stimulation, cognitive training, and exercise to potentially slow decline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
High-frequency Transcranial Magnetic Stimulation (TMS) and digital cognitive training
What this could lead to
If successful, this could lead to a way to identify people at high risk for Alzheimer's early and offer a personalized treatment plan to slow cognitive decline.
What could go wrong
This is an early, single-arm study without a control group, so results may not be definitive. The AI models may not be accurate enough, and the intervention's benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
San Raffaele Neurology Unit
Milan, Milano, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact